Clinical trials: mCRC, open to volunteers
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage.
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer, Cholangiocarcinoma
- Trial name
- ISTAR-03 (NCT07043387)
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Metastatic Colorectal Cancer (mCRC)
Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)
The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.
- Trial name
- REACH (NCT06938971)
- Testing
- Exercise training
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Colorectal Cancer Metastatic
SHR-1701 Combined with SHR2554 and BP102 for MCRC
Response to oncologic treatment in mCRC is currently limited.
- Trial name
- NCT06679673
- Testing
- SHR-1701, BP102, SHR2554
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
This study is a single-center, single-arm clinical trial involving patients with TP53-mutated and LRPPRC-positive metastatic colorectal cancer.
- Trial name
- NCT07337551
- Testing
- Gossypol acetate Combined with Bevacizumab and FOLFIRI
- Volunteers
- 20 people
- Sponsor
- Guiying Wang
Metastatic Colorectal Cancer (mCRC)
Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
DSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic…
- Trial name
- DSEE-CRC (NCT07171554)
- Testing
- µCAN drug screen test, Standard-of-Care Therapy
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oncosyne AS
Metastatic Colorectal Cancer (mCRC)
Fruquintinib in Patients With Metastatic Colorectal Cancer
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard…
- Trial name
- FRUQUENT (NCT06787105)
- Where
- 42 sites in Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
CRC (Colorectal Cancer)
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy.
- Trial name
- EpiDRIVE (NCT07224841)
- Testing
- cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- City of Hope Medical Center
mCRC
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies.
- Trial name
- NCT07116577
- Testing
- Palliative radiotherapy, Iparomlimab and tuvonralimab, TAS-102
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinan Central Hospital
Metastatic Colorectal Cancer
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination…
- Trial name
- NCT04547166
- Testing
- HLX10, HLX04、
- Where
- 5 sites in China, Japan
- Volunteers
- 568 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Colorectal Cancer
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
This study was design to: To assess the impact of a biweekly (experimental arm) compared to a conventional administration (control arm) on the rate of grade 3-4 neutropenia in metastatic colorectal cancer (mCRC) patients treated…
- Trial name
- BETWEEN (NCT07071844)
- Testing
- Trifluridine/tipiracil, Bevacizumab
- Where
- 10 sites in France
- Volunteers
- 162 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
The study is a phase II clinical study. The purpose of the study is to evaluate the efficacy and safety of SBRT combined with Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC.
- Trial name
- NCT05747716
- Testing
- SBRT, Fruquintinib, Cadonilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC…
- Trial name
- SIRtain (NCT05967143)
- Testing
- SIRT
- Where
- 9 sites in France, Spain and 1 more
- Volunteers
- 845 people
- Sponsor
- Sirtex Medical
Colorectal Cancer
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib…
- Trial name
- NCT07035886
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Takeda
Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy
- Trial name
- NCT07244705
- Testing
- ABT-301, Tislelizumab, Bevacizumab (Avastin)
- Where
- 15 sites in Australia, Taiwan
- Volunteers
- 66 people
- Sponsor
- Anbogen Therapeutics, Inc.
Metastatic Colorectal Cancer
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in…
- Trial name
- COLIBRI-GI (NCT07359456)
- Testing
- Ivonescimab, Bevacizumab, FOLFIRI Protocol
- Where
- 22 sites in France
- Volunteers
- 130 people
- Sponsor
- UNICANCER
Ras-mutated Metastatic Colorectal Cancer, mCRC
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs.
- Conditions
- Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
- Trial name
- NCT07446322
- Testing
- Bevacizumab, FOLFIRI, Pelareorep
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- Oncolytics Biotech
Metastatic Colorectal Cancer (mCRC)
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and…
- Trial name
- NCT07391566
- Testing
- LPM6690176, Bevacizumab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Luye Pharma Group Ltd.
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.